United States Diabetes Market, Size, Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis
Description
United States Diabetes Market, Size, Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis
United States Diabetes Market is expected to reach US$ 28.27 Billion by 2028, according to Renub Research. In the United States, Diabetes is the 7th leading cause of death. Diabetes is a persistent disease that happens either when the pancreas has not produced enough insulin or when the body cannot effectively and efficiently uses its insulin. In the United States, the case of diabetes has risen dramatically during the last two decades, a fact driven by the increased prevalence of obesity and lifestyle changes. Diabetes ranks among the fast-growing chronic diseases in the United States. About 1.75 Million U.S. citizens are diagnosed with diabetes every year. Diabetes and pre-diabetes are leading public health concerns across the United States. About 37.3 Million Americans have diabetes, according to the CDC.
United States Diabetes Population is expected to grow with a CAGR of 3.26% from 2022 to 2028
According to CDC, 11.3% of the U.S. population has diabetes. There are mainly two types of diabetes: type 1 and type 2. A lack of insulin production characterizes type 1 diabetes, and Type 2 diabetes is caused by the body’s ineffective use of insulin. Type 2 is typically progressive and develops in people over age 45, but there are more and more children, teenagers, and young adults who are also developing diabetes.
It often results from excess physical inactivity and body weight. Higher than 1 in 10 adults in the United States live with type 1 or 2 diabetes. Type 2 diabetes accounts for approx 90% to 95% of all diagnosed cases of diabetes; type 1 diabetes accounts for about 5-10%. Approx. 283,000 Americans under age 20 are estimated to have been diagnosed with diabetes, nearly 0.35% of that population, according to American Diabetes Association.
Although, over time, diabetes can damage the heart, blood vessels, eyes, kidneys, and nerves and increase the risk of heart disease and stroke. Such damage can result in reduced blood and nerve damage. Type 2 diabetes is a significant public health problem in the USA, affecting over 12% of American adults and imposing considerable health and economic burden on individuals and society. In the United States, 96 million adults, more than 1 in 3, have pre-diabetes.
Growing Number of Diabetic Patients in the United States will create more demand for Insulin Market
Based on devices, United State Diabetes Market is classified into four types: Glucose Monitoring (CGM), Self-Monitoring Blood Glucose (SMBG), Insulin Pen, and Insulin Pump. SMBG Capturing the maximum share during the forecast period due to monitoring blood glucose (SMBG) can be valuable in managing diabetes mellitus. Patients with diabetes often measure their blood glucose to detect hypoglycemia and adjust insulin doses as needed.
The primary growth factors include the rising diabetic population, increasing awareness among the diabetes population, increasing spending on healthcare, active reimbursement policies, and technological advancement aimed at minimal and non-invasive testing methods, which significantly boost the market.
Besides, CGM and Insulin Pens will also dominate the market revenue of the United States during the upcoming year. CGM device is a tool that measures patients glucose levels 24 hours a day. However, Insulin pens offer the advantage of ease of administration, especially for patients with visual and dexterity issues, accuracy when administering small doses, convenience, and reduced pain. Today, about 59% of patients with diabetes use insulin pens in the U.S.
United States Diabetes Market was US$ 23.32 Billion in 2022
Most of the cost of diabetes care in the U.S, is provided by government insurance (including Medicare, Medicaid, and the military). The increasing diabetes prevalence has led the Government of the U.S. to launch diabetes prevention programs, raise awareness about its symptoms and encourage healthier lifestyle behavior among the citizens. However, technological developments in diabetes devices, such as the introduction of a high-end insulin pump and pens, propel the demand for these products, leading manufacturers to focus on technological innovations and developing advanced products which boost the market.
The U.S. Diabetes Prevention Program (DPP) clinical sequent translational studies have demonstrated that intensive lifestyle interventions focused on achieving 7% weight loss and at least 150 min per week of moderate physical activity can cut the risk of developing diabetes in half. Such interventions also improve health-related quality of life and enable some patients to reduce the need for medication.
Key Companies Analysis
The United States diabetes market is moderately fragmented, with few significant and generic players. The major players are B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickinson (B.D.), Novo Nordisk, Ypsomed AG, Medtronic, Insulet Corporations, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care.
In March 2022, Dexcom released G7 first in the U.K. and will expand the launch across Europe throughout 2022. Meanwhile, the CGM system is currently under review by the Food and Drug Administration for an eventual U.S. release.
In June 2022, continuous glucose monitors (CGM) were adopted among people with type 2 diabetes (T2D). However, up to 70% of CGM use is for type 1 diabetes (T1D); only 3-4% of the U.S. T2D population use CGM despite established benefits as per One Drop.
Renub Research report titled “United States Diabetes Market & Volume Forecast by SMBG (Test Strips Market and Forecast, Lancet Market and Forecast, Meter Market and Forecast, Blood Glucose (SMBG) Users and Blood Glucose Devices Reimbursement), CGM (Glucose Sensor Market Forecast, CGM Transmitter Market & Forecast, CGM User and CGM Reimbursement, Insulin Pen (Disposable Insulin Pen, Reusable Insulin Pen, Smart Insulin Pen, Insulin Pen Needle Market ,Insulin Pen Users and Reimbursement Policies), Insulin Pump (Insulin Pump Market, Insulin Pump Users, Insulin Pump Products and Reimbursement Policies), Company Analysis (B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickinson (B.D.), Novo Nordisk, Ypsomed AG, Medtronic, Insulet Corporations, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care)’’ provides a detailed analysis of Diabetes Market in the United States.
Segments Market based on Devices
1. Continuous Glucose Monitoring (CGM)
2. Self-Monitoring Blood Glucose (SMBG)
3. Insulin Pen
4. Insulin Pump
United States Diabetes Sub-Segment Analysis
1. Continuous Glucose Monitoring (CGM) – United State Food Market breakup from four viewpoints
1. Glucose Sensor Market & Forecast
2. CGM Transmitter Market & Forecast
3. CGM User
4. CGM Reimbursement
2. SMBG – United State Food Market breakup from five viewpoints
1. Test Strips Market and Forecast
2. Lancet Market and Forecast
3. Meter Market and Forecast
4. Blood Glucose (SMBG) Users
5. Blood Glucose Devices Reimbursement
3. Insulin Pen Market – United State Food Market breakup from six viewpoints
1. Disposable Insulin Pen
2. Reusable Insulin Pen
3. Smart Insulin Pen
4. Insulin Pen Needle Market
5. Insulin Pen Users
6. Reimbursement Policies
4. Insulin Pump Market – United State Food Market breakup from four viewpoints
1. Insulin Pump Market
2. Insulin Pump Users
3. Insulin Pump Products
4. Reimbursement Policies
All the 13 Companies Studied in the Report have been Studied from 3 Points
• Company Overview
• Recent Developments
• Financial Insight
Company Analysis
1. B. Braun Melsungen AG
2. Eli Lilly and Company
3. Terumo Corporation
4. Becton, Dickinson (B.D.)
5. Novo Nordisk
6. Ypsomed AG
7. Medtronic
8. Insulet Corporations
9. Abbott Laboratories
10. DarioHealth Crop
11. Dexcom, Inc
12. Roche Diagnostic
13. Tandem Diabetes Care
United States Diabetes Market is expected to reach US$ 28.27 Billion by 2028, according to Renub Research. In the United States, Diabetes is the 7th leading cause of death. Diabetes is a persistent disease that happens either when the pancreas has not produced enough insulin or when the body cannot effectively and efficiently uses its insulin. In the United States, the case of diabetes has risen dramatically during the last two decades, a fact driven by the increased prevalence of obesity and lifestyle changes. Diabetes ranks among the fast-growing chronic diseases in the United States. About 1.75 Million U.S. citizens are diagnosed with diabetes every year. Diabetes and pre-diabetes are leading public health concerns across the United States. About 37.3 Million Americans have diabetes, according to the CDC.
United States Diabetes Population is expected to grow with a CAGR of 3.26% from 2022 to 2028
According to CDC, 11.3% of the U.S. population has diabetes. There are mainly two types of diabetes: type 1 and type 2. A lack of insulin production characterizes type 1 diabetes, and Type 2 diabetes is caused by the body’s ineffective use of insulin. Type 2 is typically progressive and develops in people over age 45, but there are more and more children, teenagers, and young adults who are also developing diabetes.
It often results from excess physical inactivity and body weight. Higher than 1 in 10 adults in the United States live with type 1 or 2 diabetes. Type 2 diabetes accounts for approx 90% to 95% of all diagnosed cases of diabetes; type 1 diabetes accounts for about 5-10%. Approx. 283,000 Americans under age 20 are estimated to have been diagnosed with diabetes, nearly 0.35% of that population, according to American Diabetes Association.
Although, over time, diabetes can damage the heart, blood vessels, eyes, kidneys, and nerves and increase the risk of heart disease and stroke. Such damage can result in reduced blood and nerve damage. Type 2 diabetes is a significant public health problem in the USA, affecting over 12% of American adults and imposing considerable health and economic burden on individuals and society. In the United States, 96 million adults, more than 1 in 3, have pre-diabetes.
Growing Number of Diabetic Patients in the United States will create more demand for Insulin Market
Based on devices, United State Diabetes Market is classified into four types: Glucose Monitoring (CGM), Self-Monitoring Blood Glucose (SMBG), Insulin Pen, and Insulin Pump. SMBG Capturing the maximum share during the forecast period due to monitoring blood glucose (SMBG) can be valuable in managing diabetes mellitus. Patients with diabetes often measure their blood glucose to detect hypoglycemia and adjust insulin doses as needed.
The primary growth factors include the rising diabetic population, increasing awareness among the diabetes population, increasing spending on healthcare, active reimbursement policies, and technological advancement aimed at minimal and non-invasive testing methods, which significantly boost the market.
Besides, CGM and Insulin Pens will also dominate the market revenue of the United States during the upcoming year. CGM device is a tool that measures patients glucose levels 24 hours a day. However, Insulin pens offer the advantage of ease of administration, especially for patients with visual and dexterity issues, accuracy when administering small doses, convenience, and reduced pain. Today, about 59% of patients with diabetes use insulin pens in the U.S.
United States Diabetes Market was US$ 23.32 Billion in 2022
Most of the cost of diabetes care in the U.S, is provided by government insurance (including Medicare, Medicaid, and the military). The increasing diabetes prevalence has led the Government of the U.S. to launch diabetes prevention programs, raise awareness about its symptoms and encourage healthier lifestyle behavior among the citizens. However, technological developments in diabetes devices, such as the introduction of a high-end insulin pump and pens, propel the demand for these products, leading manufacturers to focus on technological innovations and developing advanced products which boost the market.
The U.S. Diabetes Prevention Program (DPP) clinical sequent translational studies have demonstrated that intensive lifestyle interventions focused on achieving 7% weight loss and at least 150 min per week of moderate physical activity can cut the risk of developing diabetes in half. Such interventions also improve health-related quality of life and enable some patients to reduce the need for medication.
Key Companies Analysis
The United States diabetes market is moderately fragmented, with few significant and generic players. The major players are B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickinson (B.D.), Novo Nordisk, Ypsomed AG, Medtronic, Insulet Corporations, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care.
In March 2022, Dexcom released G7 first in the U.K. and will expand the launch across Europe throughout 2022. Meanwhile, the CGM system is currently under review by the Food and Drug Administration for an eventual U.S. release.
In June 2022, continuous glucose monitors (CGM) were adopted among people with type 2 diabetes (T2D). However, up to 70% of CGM use is for type 1 diabetes (T1D); only 3-4% of the U.S. T2D population use CGM despite established benefits as per One Drop.
Renub Research report titled “United States Diabetes Market & Volume Forecast by SMBG (Test Strips Market and Forecast, Lancet Market and Forecast, Meter Market and Forecast, Blood Glucose (SMBG) Users and Blood Glucose Devices Reimbursement), CGM (Glucose Sensor Market Forecast, CGM Transmitter Market & Forecast, CGM User and CGM Reimbursement, Insulin Pen (Disposable Insulin Pen, Reusable Insulin Pen, Smart Insulin Pen, Insulin Pen Needle Market ,Insulin Pen Users and Reimbursement Policies), Insulin Pump (Insulin Pump Market, Insulin Pump Users, Insulin Pump Products and Reimbursement Policies), Company Analysis (B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickinson (B.D.), Novo Nordisk, Ypsomed AG, Medtronic, Insulet Corporations, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care)’’ provides a detailed analysis of Diabetes Market in the United States.
Segments Market based on Devices
1. Continuous Glucose Monitoring (CGM)
2. Self-Monitoring Blood Glucose (SMBG)
3. Insulin Pen
4. Insulin Pump
United States Diabetes Sub-Segment Analysis
1. Continuous Glucose Monitoring (CGM) – United State Food Market breakup from four viewpoints
1. Glucose Sensor Market & Forecast
2. CGM Transmitter Market & Forecast
3. CGM User
4. CGM Reimbursement
2. SMBG – United State Food Market breakup from five viewpoints
1. Test Strips Market and Forecast
2. Lancet Market and Forecast
3. Meter Market and Forecast
4. Blood Glucose (SMBG) Users
5. Blood Glucose Devices Reimbursement
3. Insulin Pen Market – United State Food Market breakup from six viewpoints
1. Disposable Insulin Pen
2. Reusable Insulin Pen
3. Smart Insulin Pen
4. Insulin Pen Needle Market
5. Insulin Pen Users
6. Reimbursement Policies
4. Insulin Pump Market – United State Food Market breakup from four viewpoints
1. Insulin Pump Market
2. Insulin Pump Users
3. Insulin Pump Products
4. Reimbursement Policies
All the 13 Companies Studied in the Report have been Studied from 3 Points
• Company Overview
• Recent Developments
• Financial Insight
Company Analysis
1. B. Braun Melsungen AG
2. Eli Lilly and Company
3. Terumo Corporation
4. Becton, Dickinson (B.D.)
5. Novo Nordisk
6. Ypsomed AG
7. Medtronic
8. Insulet Corporations
9. Abbott Laboratories
10. DarioHealth Crop
11. Dexcom, Inc
12. Roche Diagnostic
13. Tandem Diabetes Care
Table of Contents
125 Pages
- 1. Introduction
- 2. Research & Methodology
- 3. Executive Summary
- 4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
- 5. United States Diabetes Market
- 6. United States Diabetes Population & Forecast
- 6.1 Type 1 Diabetes
- 6.2 Type 2 Diabetes
- 7. Market Share – United States Diabetes Analysis
- 7.1 By Types
- 8. Continuous Glucose Monitoring Market (CGM) – Market & Users
- 8.1 CGM Market by Components
- 8.1.1 Glucose Sensor Market
- 8.1.2 CGM Transmitter Market
- 8.2 CGM User
- 8.3 Reimbursement Policies of CGM Devices in United States
- 9. Blood Glucose Device (SMBG) – United States Market & Users
- 9.1 Market
- 9.1.1 Type 1 (SMBG)
- 9.1.2 Type 2 (SMBG)
- 9.2 Test Strips Market
- 9.2.1 Type 1
- 9.2.2 Type 2
- 9.3 Lancet Market and Forecast
- 9.3.1 Type 1
- 9.3.2 Type 2
- 9.4 Meter Market and Forecast
- 9.4.1 Type 1
- 9.4.2 Type 2
- 9.5 Blood Glucose (SMBG) Users
- 9.5.1 Type 1
- 9.5.2 Type 2
- 9.6 Reimbursement Policies of Blood Glucose Devices in United States
- 10. Insulin Pen – United States Market & User
- 10.1 Insulin Pen Market
- 10.1.1 Disposable Insulin Pen
- 10.1.2 Reusable Insulin Pen
- 10.1.3 Smart Insulin Pen
- 10.2 Insulin Pen User
- 10.2.1 Disposable Insulin Pen
- 10.2.2 Reusable Insulin Pen
- 10.2.3 Smart Insulin Pen
- 10.3 Insulin Pen Needle Market
- 10.4 Reimbursement Policies of Insulin Pen in United States
- 11. Insulin Pump - United States Market & Users
- 11.1 Insulin Pump Market
- 11.1.1 Type 1
- 11.1.2 Type 2
- 11.2 Insulin Pump User
- 11.2.1 Type 1
- 11.2.2 Type 2
- 11.3 Differentiation Points of Insulin Pump Products in United States
- 11.3.1 Animas Vibe
- 11.3.2 Medtronic 530G with Enlite
- 11.3.3 Insulet OmniPod
- 11.3.4 Tandem t: slim
- 11.3.5 Roche Accu-Chek Combo
- 11.4 Training Model for Patients & HCP – of Medtronic, Animas, Insulet Corp & Tandem Diabetes Care
- 11.4.1 Medtronic
- 11.5 Insulet Corporation
- 11.5.1 Training Structure for New Patients - Insulet Corporation
- 11.6 Animas Corporation
- 11.6.1 Training Modules for New Patients
- 11.6.2 Training Modules for HCP (Health Care Professional)
- 11.7 Tandem Diabetes Care
- 11.8 Reimbursement Policies on Insulin Pump
- 12. Insulin Pen – Company Analysis
- 12.1 B. Braun Melsungen AG
- 12.1.1 Overview
- 12.1.2 Recent Development
- 12.1.3 Revenue
- 12.2 Eli Lilly
- 12.2.1 Overview
- 12.2.2 Recent Development
- 12.2.3 Revenue
- 12.3 Terumo Corporation
- 12.3.1 Overview
- 12.3.2 Recent Development
- 12.3.3 Revenue
- 12.4 BD
- 12.4.1 Overview
- 12.4.2 Recent Development
- 12.4.3 Revenue
- 12.5 Novo Nordisk A/S
- 12.5.1 Overview
- 12.5.2 Recent Development
- 12.5.3 Revenue
- 12.6 Ypsomed AG
- 12.6.1 Overview
- 12.6.2 Recent Development
- 12.6.3 Revenue
- 13. Insulin Pump – Company Analysis
- 13.1 Medtronic
- 13.1.1 Overview
- 13.1.2 Recent Development
- 13.1.3 Revenue
- 13.2 Insulet Corporation
- 13.2.1 Overview
- 13.2.2 Recent Development
- 13.2.3 Revenue
- 14. SMBG – Company Analysis
- 14.1 DarioHealth Corp
- 14.1.1 Overview
- 14.1.2 Recent Development
- 14.1.3 Revenue
- 14.2 Abbott Laboratories
- 14.2.1 Overview
- 14.2.2 Recent Development
- 14.2.3 Revenue
- 15. CGM – Company Analysis
- 15.1 Dexcom Inc
- 15.1.1 Overview
- 15.1.2 Recent Development
- 15.1.3 Revenue
- 15.2 Roche
- 15.2.1 Overview
- 15.2.2 Recent Development
- 15.2.3 Revenue
- 15.3 Tandem Diabetes Care
- 15.3.1 Overview
- 15.3.2 Recent Development
- 15.3.3 Revenue
- List of Figures:
- Figure-01: United States – Diabetes Market (Billion US$), 2017 – 2022
- Figure-02: United States – Forecast for Diabetes Market (Billion US$), 2023 – 2028
- Figure-03: United States – Type 1 Diabetes Population (Thousand), 2017 – 2022
- Figure-04: United States – Forecast for Type 1 Diabetes Population (Thousand), 2023 – 2028
- Figure-05: United States – Type 2 Diabetes Population (Thousand), 2017 – 2022
- Figure-06: United States – Forecast for Type 2 Diabetes Population (Thousand), 2023 – 2028
- Figure-07: United States – Glucose Sensor Market Market (Million US$), 2017 – 2023
- Figure-08: United States – Forecast for Glucose Sensor Market Market (Million US$), 2023 – 2028
- Figure-09: United States – CGM Transmitter Market Market (Million US$), 2017 – 2023
- Figure-10: United States – Forecast for CGM Transmitter Market Market (Million US$), 2023 – 2028
- Figure-11: United States – CGM User (Thousand), 2017 – 2023
- Figure-12: United States – Forecast for CGM User (Thousand),2023 – 2028
- Figure-13: United States – Self-Monitoring of Blood Glucose (SMBG) Type 1 Diabetes Market (Million US$), 2023 – 2028
- Figure-14: United States – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 1 Diabetes Market (Million US$), 2017 – 2023
- Figure-15: United States – Self-Monitoring of Blood Glucose (SMBG) Type 2 Diabetes Market (Million US$), 2023 – 2028
- Figure-16: United States – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 2 Diabetes Market (Million US$), 2017 – 2023
- Figure-17: United States – Test Strips Type 1 Diabetes Market (Million US$), 2023 – 2028
- Figure-18: United States – Forecast for Test Strips Type 1 Diabetes Market (Million US$), 2017 – 2023
- Figure-19: United States – Test Strips Type 2 Diabetes Market (Million US$), 2023 – 2028
- Figure-20: United States – Forecast for Test Strips Type 2 Diabetes Market (Million US$), 2017 – 2023
- Figure-21: United States – Lancet Type 1 Diabetes Market (Million US$), 2023 – 2028
- Figure-22: United States – Forecast for Lancet Type 1 Diabetes Market (Million US$), 2017 – 2023
- Figure-23: United States – Lancet Type 2 Diabetes Market (Million US$), 2023 – 2028
- Figure-24: United States – Forecast for Lancet Type 2 Diabetes Market (Million US$), 2017 – 2023
- Figure-25: United States – Meter Type 1 Diabetes Market (Million US$), 2023 – 2028
- Figure-26: United States – Forecast for Meter Type 1 Diabetes Market (Million US$), 2017 – 2023
- Figure-27: United States – Meter Type 2 Diabetes Market (Million US$), 2023 – 2028
- Figure-28: United States – Forecast for Meter Type 2 Diabetes Market (Million US$), 2017 – 2023
- Figure-29: United States – Self-Monitoring of Blood Glucose (SMBG) Type 1 Users (Thousand), 2017 – 2022
- Figure-30: United States – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 1 Users (Thousand), 2023 – 2028
- Figure-31: United States – Self-Monitoring of Blood Glucose (SMBG) Type 2 Users (Thousand), 2017 – 2022
- Figure-32: United States – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 2 Users (Thousand), 2023 – 2028
- Figure-33: United States – Disposable Insulin Pen Market (Million US$), 2017 – 2023
- Figure-34: United States – Forecast for Disposable Insulin Pen Market (Million US$), 2023 – 2028
- Figure-35: United States – Reusable Insulin Pen Market (Million US$), 2017 – 2023
- Figure-36: United States – Forecast for Reusable Insulin Pen Market (Million US$), 2023 – 2028
- Figure-37: United States – Smart Insulin Pen Market (Million US$), 2017 – 2023
- Figure-38: United States – Forecast for Smart Insulin Pen Market (Million US$), 2023 – 2028
- Figure-39: United States – Disposable Insulin Pen User (Thousand), 2017 – 2022
- Figure-40: United States – Forecast for Disposable Insulin Pen User (Thousand), 2023 – 2028
- Figure-41: United States – Reusable Insulin Pen User (Thousand), 2017 – 2022
- Figure-42: United States – Forecast for Reusable Insulin Pen User (Thousand), 2023 – 2028
- Figure-43: United States – Smart Insulin Pen User (Thousand), 2017 – 2022
- Figure-44: United States – Forecast for Smart Insulin Pen User (Thousand), 2023 – 2028
- Figure-45: United States – Insulin Pen Needle Market Market (Million US$), 2017 – 2023
- Figure-46: United States – Forecast for Pen Needle Market for Market (Million US$), 2023 – 2028
- Figure-47: United States – Insulin Pump Market for Type 1 Diabetes Market (Million US$), 2017 – 2023
- Figure-48: United States – Forecast for Insulin Pump Market for Type 1 Diabetes Market (Million US$), 2023 – 2028
- Figure-49: United States – Insulin Pump Market for Type 2 Diabetes Market (Million US$), 2017 – 2023
- Figure-50: United States – Forecast for Insulin Pump Market for Type 2 Diabetes Market (Million US$), 2023 – 2028
- Figure-51: United States – Insulin Pump Type 1 Users (Thousand), 2017 – 2022
- Figure-52: United States – Forecast for Insulin Pump Type 1 Users (Thousand), 2023 – 2028
- Figure-53: United States – Insulin Pump Type 2 Users (Thousand), 2017 – 2022
- Figure-54: United States – Forecast for Insulin Pump Type 2 Users (Thousand), 2023 – 2028
- Figure-55: B. Braun Melsungen AG – Global Revenue (Billion US$), 2017 – 2022
- Figure-56: B. Braun Melsungen AG – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-57: Eli Lilly – Global Revenue (Billion US$), 2017 – 2022
- Figure-58: Eli Lilly – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-59: Terumo Corporation – Global Revenue (Billion US$), 2017 – 2022
- Figure-60: Terumo Corporation – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-61: BD – Global Revenue (Billion US$), 2017 – 2022
- Figure-62: BD – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-63: Novo Nordisk A/S – Global Revenue (Billion US$), 2017 – 2022
- Figure-64: Novo Nordisk A/S – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-65: Ypsomed AG – Global Revenue (Billion US$), 2017 – 2022
- Figure-66: Ypsomed AG – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-67: Medtronic – Global Revenue (Billion US$), 2017 – 2022
- Figure-68: Medtronic – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-69: Insulet Corporation – Global Revenue (Billion US$), 2017 – 2022
- Figure-70: Insulet Corporation – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-71: DarioHealth Corp – Global Revenue (Billion US$), 2017 – 2022
- Figure-72: DarioHealth Corp – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-73: Abbott Laboratories – Global Revenue (Billion US$), 2017 – 2022
- Figure-74: Abbott Laboratories – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-75: Dexcom Inc – Global Revenue (Billion US$), 2017 – 2022
- Figure-76: Dexcom Inc – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-77: Roche – Global Revenue (Billion US$), 2017 – 2022
- Figure-78: Roche – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-79: Tandem Diabetes Care – Global Revenue (Billion US$), 2017 – 2022
- Figure-80: Tandem Diabetes Care – Forecast for Global Revenue (Billion US$), 2023 – 2028
- List of Tables:
- Table-01: United States – Diabetes Market Share by Type (Percent), 2017 – 2022
- Table-02: United States – Forecast for Diabetes Market Share by Type (Percent), 2023 – 2028
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
